The University of Chicago has funding for Paul Calabresi Scholars in Clinical Oncology K12 Scholar positions that will provide substantial salary support (up to $100,000 plus fringe) for advanced postdoctoral scholars and faculty-level clinical and translational scientists near the beginning of their investigative careers. Applications are for funding in 2019-2020, and appointments can begin as early as (July 1, 2019). Appointments of Scholars to the Paul Calabresi K12 program are for a minimum of 2 years but in very rare circumstances individual scholars can be supported for up to 3 years. Eligible candidates must hold a doctoral degree and must have a faculty appointment or be eligible for a “Pathway to Independence” University of Chicago appointment (BSD, SOM, RA) appointment during the period of support. Graduate students are not eligible but highly competitive advanced postdoctoral fellows interested in translational research can be considered.

For the purposes of this award, and in agreement with the recommendations of the NIH Director's Panel on Clinical Research, (http://www.nih.gov/news/crp/97report/index.htm), patient-oriented research is defined as research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena for which an investigator directly interacts with human subjects). This area of research includes 1) mechanisms of human disease; 2) therapeutic interventions; 3) clinical trials; and 4) the development of biomarkers and new technologies. Research topics can relate to any aspect of clinical and/or translational research, relevant to any patient population and disease group, and employing any suitable research approach. However, potential relevance to clinical oncology therapeutic research must be demonstrated.

OVERVIEW OF THE CALABRESI K12 MECHANISM

Paul Calabresi K12 Scholars are to be relatively new investigators, at the senior postdoctoral or junior faculty level of Assistant Professor or Instructor, who are committed to a career in clinical and/or translational research.

The goal of the program is to train scholars to 1) primarily perform clinical oncology therapeutic research that develops and tests scientific hypotheses based on basic science and clinical research findings; 2) design and test hypothesis-based, clinical therapeutic protocols and adjunct biological analyses and for clinician candidates to administer all phases (i.e., pilot/Phase I, Phase II, and Phase III) of cancer therapeutic clinical trials, and 3) conduct cancer therapeutic research in team research settings in which basic research and clinical scientists collaborate and interact to expedite the translation of basic science research discoveries into patient-oriented therapeutic cancer research.

EXPECTATIONS OF CALABRESI K12 SCHOLARS

• Candidates are expected to assemble a multidisciplinary mentoring committee of senior advisors/mentors and meet with their mentors at least twice a year.
• All K12 Scholars are expected to participate in the Institute for Translational Medicine K Scholars monthly Seminar Series, as well as other educational seminars, as appropriate to their areas of study.
• Participate in Institutionally supported K grant writing series or R Studio. A crucial expectation of the awardees is that preliminary data will be developed which will serve as the basis for an NIH grant application (or equivalent – ACS, ASCO CDA) in clinical and/or translational research.
• Awardees will be expected to submit reports on a yearly basis or more frequently as requested by Training Program leadership.

K12 SCHOLAR APPLICATION

The next review meeting is scheduled for October 2019 and applications must be submitted online using the Paul Calabresi K12 Career Development Program Application (https://redcap.uchicago.edu/surveys/?s=XR4AP7CE9E), by Friday, September 27, 2019 at 11:59:59 pm. Applications will not be accepted after the deadline, so please start planning for questions and last-minute submission problems.

Applications must include the following:

1. A full curriculum vitae (not an NIH Biosketch).
2. A one-page description of candidate’s commitment to an academic career in patient-oriented research. Include a description of all professional responsibilities and show their relation to the proposed activities on the career award.
3. A one-page detailed, structured training plan to be undertaken during the appointment period.
4. A seven-page research plan including Specific Aims (1 page) and Research Strategy (6 pages), the latter including Significance, Innovation, Approach, Impact, and Preliminary Studies. In addition (no page restriction), please include Literature Cited and information regarding Human Subjects and Vertebrate Animals as appropriate.
5. A brief letter from the Department Chair or Section Leader addressing:
   a. The candidate’s prospects for development into an independently funded clinical/translational scientist;
   b. The Department’s assurance that at least 75% of the candidate’s time will be protected for research career development and devoted to her/his role as a K12 Scholar (at least 50% for clinicians);
   c. Names of the proposed mentors who will constitute a multidisciplinary mentoring committee for the Scholar (a minimum of two disciplines must be represented)
6. A brief letter from the candidate’s mentors, indicating their commitment to the candidate and endorsement of the candidate’s training plan.

All uploaded application documents must be in PDF format, with a minimum ½” margins and 11 pt. font.

Applications by women, underrepresented minorities, individuals from disadvantaged backgrounds, and individuals with disabilities remain a high priority for funding. The academic and intellectual background, motivation, and commitment of the candidate to pursue clinical and/or translational research will be evaluated.

The criteria for selecting awardees will include assessment of the candidate’s potential, the dedication to clinical and/or translational research, and the degree of support from the Department.

Application deadline is 11:59:59 pm CST, (September 27th, 2019).